MK-7075 (Miransertib) in Proteus Syndrome | MicrobiomeTrials← Back to trialsNCT04316546
MK-7075 (Miransertib) in Proteus Syndrome
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2022-05-20Est. Completion: 2026-06-25
Enrollment target: 38 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Proteus SyndromePIK3CA Related Overgrowth Spectrum
This study will examine rare congenital disorders that involve malformations and abnormal growth. It will focus on patie…
Bethesda, United States
SepsisSeptic Shock
Introduction: Timely and accurate antibiotic administration in emergency department (ED) patients with sepsis or septic …
Multiple LocationsEst. completion Oct 20, 2025